Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, ME, USA.
Chest Medicine Associates, Portland, ME, USA.
Med Decis Making. 2019 Nov;39(8):950-961. doi: 10.1177/0272989X19875966. Epub 2019 Oct 20.
Low-dose computed tomography (LDCT) screening for lung cancer is a preference-sensitive intervention that should ideally be individualized according to patients' likelihood of benefit and personal values. Personalized cancer risk information (PCRI) may facilitate this goal, but its effects are unknown. To evaluate the effects of providing PCRI to patients referred for LDCT screening. Mixed-methods, pre-post study using surveys administered to patients before and after provision of PCRI-calculated by the PLCOm2012 risk prediction model-in shared decision-making consultations, and postvisit qualitative interviews. Centralized specialty-based LDCT screening program at a tertiary care hospital. Convenience sample of eligible patients referred for LDCT screening. Pre- and postvisit surveys assessed patients' 1) perceived lung cancer risk, 2) uncertainty about their risk, 3) minimum risk threshold for wanting screening, 4) interest in LDCT screening, and 5) interest in smoking cessation. Qualitative interviews explored patients' perceptions of the value of PCRI. Screening uptake was assessed by chart review. Sixty of 70 (86%) patients received PCRI and completed pre-post surveys, and 17 patients (28%) completed qualitative interviews. Perceived lung cancer risk decreased from 52% previsit to 31% postvisit ( < 0.0001). However, patients' minimum risk thresholds for screening decreased, their screening interest increased, and all patients completed screening. Qualitative interviews corroborated these effects, suggesting that patients discount and interpret PCRI according to preexisting beliefs and attitudes. The study population was a relatively small, single-institution sample of patients referred for screening. Personalized cancer risk information decreases cancer risk perceptions of patients referred for LDCT screening, but has complex effects on screening-related judgments and decisions. The value of PCRI for patients considering LDCT screening requires further investigation.
低剂量计算机断层扫描(LDCT)筛查肺癌是一种偏好敏感的干预措施,理想情况下应根据患者的获益可能性和个人价值观进行个体化。个性化癌症风险信息(PCRI)可能有助于实现这一目标,但效果尚不清楚。 评估为接受 LDCT 筛查的患者提供 PCRI 的效果。 采用混合方法,在提供 PCRI 前后对患者进行问卷调查,PCRI 由 PLCOm2012 风险预测模型计算,并在共同决策咨询中进行,然后进行随访定性访谈。 三级保健医院的集中专业 LDCT 筛查计划。 从接受 LDCT 筛查的合格患者中抽取方便样本。 就诊前和就诊后调查评估了患者的 1)肺癌风险感知,2)对其风险的不确定性,3)希望进行筛查的最低风险阈值,4)对 LDCT 筛查的兴趣,以及 5)对戒烟的兴趣。定性访谈探讨了患者对 PCRI 价值的看法。通过病历审查评估筛查参与度。 70 名患者中的 60 名(86%)接受了 PCRI 并完成了就诊前和就诊后调查,17 名患者(28%)完成了定性访谈。就诊前的肺癌风险感知从 52%下降到就诊后的 31%(<0.0001)。然而,患者的最低筛查风险阈值降低,他们的筛查兴趣增加,所有患者都完成了筛查。定性访谈证实了这些影响,表明患者根据预先存在的信念和态度来贴现和解释 PCRI。 研究人群是一个相对较小的、单一机构的筛查患者样本。 个性化癌症风险信息降低了接受 LDCT 筛查的患者的癌症风险感知,但对与筛查相关的判断和决策有复杂的影响。考虑进行 LDCT 筛查的患者对 PCRI 的价值需要进一步研究。